Pharmafile Logo
Pharmafocus logo
Advanced Search

Jevtana

Showing 15 posts of 18 posts found.

Sanofi’s Jevtana doubles progression-free survival in metastatic castration-resistant prostate cancer

October 1, 2019
Manufacturing and Production, Research and Development ESMO 2019, Jevtana, Sanofi, pharma, prostate cancer

Sanofi was present at the 2019 European Society of Medical Oncology (ESMO) Congress in Barcelona this year to reveal new …

News
jevtana_0

Scottish Medicines Consortium approves Sanofi’s prostate cancer drug

December 12, 2016
Manufacturing and Production, Sales and Marketing Jevtana, Sanofi, prostate cancer

Sanofi’s speciality care global business unit Sanofi Genzyme has announced that the Scottish Medicines Consortium has accepted the company’s Jevtana …

News

NICE recommends Jevtana for advanced prostate cancer

May 25, 2016
Sales and Marketing Jevtana, NICE, approval, prostate cancer, recommendation

The National Institute for Health and Care Excellence (NICE) has recommended Sanofi Genzyme’s Jevtana (cabazitaxel), in combination with prednisone or …

News
jevtana

A win for Sanofi on Jevtana after NICE reverses guidance

April 22, 2016
Medical Communications, Sales and Marketing Cancer Drugs Fund, Jevtana, NICE, Sanofi, recommendation, reversal

Prostate cancer treatment Jevtana (cabazitaxel), marketed by Sanofi (NYSE: SNY) has been recommended by NICE in its final guidance. The …

News
Sanofi image

Oncologists say CDF cuts will compromise treatment

March 10, 2015
Sales and Marketing CDF, Jevtana, NHS, NICE, Sanofi, cabazitaxel, doctors.net, m3

Oncologists believe cutting drugs from the Cancer Drugs Fund won’t save the NHS money and will worsen patient outcomes according …

News
cancer image

Half of UK population will get cancer

February 4, 2015
Research and Development, Sales and Marketing CDF, CRUK, Cancer, Jevtana, Sanofi, cabazitaxel

New figures from Cancer Research UK (CRUK) suggest that one in two people will develop cancer at some point in …

News

NHS drops 25 treatments from Cancer Drugs Fund

January 12, 2015
Sales and Marketing Afinitor, CDF, Cancer, Cancer Drugs Fund, Eisa, Halaven, Heribulin, Jevtana, NHS, Sanofi, Zaltrap, aflibercept, cabazitaxel, everolimus

Twenty-five cancer treatments will be removed from the Cancer Drugs Fund list, NHS England has announced. Having concluded its review …

News
Afinitor image

Exclusive: Novartis drug struck off cancer drugs fund

January 8, 2015
Sales and Marketing Afinitor, Jevtana, NHS, NHS England, NICE, Novartis, Sanofi, everolimus

Novartis’ Afinitor (everolimus) will be removed from the Cancer Drugs Fund list when NHS England announces which drugs it can …

News

Sanofi cleared in sales row

September 20, 2012
Medical Communications, Sales and Marketing ABPI, CDF, Jevtana, PMCPA, Sanofi

Sanofi has been cleared of any wrongdoing after allegations that it had broken multiple clauses in the ABPI Code of …

News
Zytiga image

Price cut sways NICE on Zytiga

May 16, 2012
Sales and Marketing Jevtana, NICE, Zytiga, prostate cancer

NICE is recommending Janssen’s prostate cancer pill Zytiga, reversing its previous stance.  In its final guidance, the watchdog is recommending …

News
NICE picture

NICE rejects Sanofi’s Jevtana

January 12, 2012
Sales and Marketing Jevtana, NICE, Sanofi, Zytiga

NICE is not recommending Sanofi’s prostate cancer drug Jevtana due to its high cost and questions over its safety. In …

News
Gilenya picture

Key product launches of 2011

December 19, 2011
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Actos, Benlysta, Brilique, Eliquis, Eylea, Incivek, Jevtana, Multaq, Victrelis, Xalkori, Yervoy, Zytiga, avastin, gilenya, key products

 Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …

Feature

NICE refuses to back Sanofi’s Jevtana

September 30, 2011
Sales and Marketing Jevtana, NICE

NICE has not recommended Sanofi’s prostate cancer drug Jevtana due to its high cost and concerns over its safety data. …

News
Zytiga

European approval for prostate cancer drug Zytiga

September 8, 2011
Sales and Marketing Janssen, Jevtana, Johnson & Johnson, Zytiga, prostate cancer

Johnson & Johnson’s Zytiga has been approved in the EU for late-stage prostate cancer. Zytiga (abiraterone acetate) is now licenced …

News
Sanofi

Sanofi launches Jevtana in UK

July 6, 2011
Sales and Marketing Jevtana, Sanofi, prostate cancer

Sanofi has launched its promising advanced prostate cancer drug Jevtana in the UK following EMA approval in March. Jevtana (cabazitaxel) …

News

Latest content

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024

PeptiDream and Novartis extend peptide discovery collaboration

April 30, 2024

Pfizer’s Beqvez approved by FDA for haemophilia B treatment

April 29, 2024